-
公开(公告)号：US20230383008A1
公开(公告)日：2023-11-30
申请号：US18048763
申请日：2022-10-21
Applicant: Genentech, Inc.
Inventor： Robert F. KELLEY , Daniel K. Kirchhofer , Joyce Lai , Chingwei V. Lee , Wei-Ching Liang , Michael T. Lipari , Kelly M. Loyet , Tao Sai , Menno Van Lookeren Campagne , Yan Wu , Germaine Fuh
IPC: C07K16/40 , A61K39/395
CPC classification number: C07K16/40 , A61K39/3955 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2039/507
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
-
公开(公告)号：US11512143B2
公开(公告)日：2022-11-29
申请号：US16543818
申请日：2019-08-19
Applicant: Genentech, Inc.
Inventor： Robert F. Kelley , Daniel K. Kirchhofer , Joyce Lai , Chingwei V. Lee , Wei-Ching Liang , Michael T. Lipari , Kelly M. Loyet , Tao Sai , Menno Van Lookeren Campagne , Yan Wu , Germaine Fuh
IPC: C07K16/40 , A61K39/395 , A61K39/00
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
-
公开(公告)号：US09102720B2
公开(公告)日：2015-08-11
申请号：US13919137
申请日：2013-06-17
Applicant: Genentech, Inc.
Inventor： Anil D. Bagri , Germaine Fuh , Chingwei V. Lee
IPC: C07K16/22 , A61K39/395 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , A61K2300/00
Abstract: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.
Abstract translation: 本发明提供VEGF-C拮抗剂，例如抗VEGF-C抗体，以及它们在预防和治疗肿瘤进展中的用途。
-
公开(公告)号：US10421821B2
公开(公告)日：2019-09-24
申请号：US15336171
申请日：2016-10-27
Applicant: Genentech, Inc.
Inventor： Robert F. Kelley , Daniel K. Kirchhofer , Joyce Lai , Chingwei V. Lee , Wei-Ching Liang , Michael T. Lipari , Kelly M. Loyet , Tao Sai , Menno Van Lookeren Campagne , Yan Wu , Germaine Fuh
IPC: A61K39/00 , A61K39/395 , C07K16/40
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
-
公开(公告)号：US20190048097A1
公开(公告)日：2019-02-14
申请号：US16168503
申请日：2018-10-23
Applicant: Genentech, Inc.
Inventor： Robert F. Kelley , Daniel K. Kirchhofer , Joyce Lai , Chingwei V. Lee , Wei-Ching Liang , Michael T. Lipari , Kelly M. Loyet , Tao Sai , Menno Van Lookeren Campagne , Yan Wu , Germaine Fuh
CPC classification number: C07K16/40 , A61K39/3955 , A61K2039/507 , C07K2317/24 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
-
Patent Agency Ranking
公开(公告)号：US09777059B2
公开(公告)日：2017-10-03
申请号：US14548818
申请日：2014-11-20
Applicant: Genentech, Inc.
Inventor： Germaine Fuh , Chingwei V. Lee
CPC classification number: C07K16/22 , A61K2039/505 , C07K16/005 , C07K16/32 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/92 , G01N33/6893 , G01N2333/475
Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
-
公开(公告)号：US10421822B2
公开(公告)日：2019-09-24
申请号：US16168503
申请日：2018-10-23
Applicant: Genentech, Inc.
Inventor： Robert F. Kelley , Daniel K. Kirchhofer , Joyce Lai , Chingwei V. Lee , Wei-Ching Liang , Michael T. Lipari , Kelly M. Loyet , Tao Sai , Menno Van Lookeren Campagne , Yan Wu , Germaine Fuh
IPC: C07K16/40 , A61K39/395 , A61K39/00
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
-
公开(公告)号：US12006360B2
公开(公告)日：2024-06-11
申请号：US16860891
申请日：2020-04-28
Applicant: Genentech, Inc.
Inventor： Germaine Fuh , Chingwei V. Lee , Patrick Koenig
IPC: A61K39/395 , A61K45/06 , C07K16/24 , C07K16/46 , A61K39/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K16/247 , C07K16/468 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
Abstract: The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.
-
公开(公告)号：US10683348B2
公开(公告)日：2020-06-16
申请号：US15167030
申请日：2016-05-27
Applicant: Genentech, Inc.
Inventor： Germaine Fuh , Chingwei V. Lee , Patrick Koenig
IPC: C07K16/32 , C07K16/28 , C07K16/22 , C07K16/42 , C07K16/46 , A61K39/00 , C07K16/24 , A61K39/395 , A61K45/06
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
-
公开(公告)号：US20130344072A1
公开(公告)日：2013-12-26
申请号：US13919137
申请日：2013-06-17
Applicant: GENENTECH, INC.
Inventor： Anil D. Bagri , Germaine Fuh , Chingwei V. Lee
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , A61K2300/00
Abstract: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.
Abstract translation: 本发明提供VEGF-C拮抗剂，例如抗VEGF-C抗体，以及它们在预防和治疗肿瘤进展中的用途。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.01 seconds)
